Bionovo, Inc. (Nasdaq: BNVI) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo's proprietary drug candidate Bezielle® (BZL101) for the treatment of metastatic breast cancer. The patent issued is Bionovo's second issued patent, with over 70 other patent applications currently pending. Bionovo's US Patent No...
More...